

Lisa Salvatore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9031068/publications.pdf>

Version: 2024-02-01

94
papers

4,499
citations

147801

31
h-index

102487

66
g-index

96
all docs

96
docs citations

96
times ranked

5875
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 549-555. | 5.0 | 2 |
| 2 | Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O ⁶ -Methylguanine- ⁶ -DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1562-1573. | 1.6 | 52 |
| 3 | Management of single pulmonary metastases from colorectal cancer: State of the art. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 820-832. | 2.0 | 10 |
| 4 | Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 172, 171-181. | 2.8 | 14 |
| 5 | Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis. <i>Cancers</i> , 2021, 13, 574. | 3.7 | 6 |
| 6 | A Novel ATM Pathogenic Variant in an Italian Woman with Gallbladder Cancer. <i>Genes</i> , 2021, 12, 313. | 2.4 | 2 |
| 7 | Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021, 146, 145-154. | 2.8 | 8 |
| 8 | Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study). <i>Cancers</i> , 2021, 13, 2098. | 3.7 | 5 |
| 9 | Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection. <i>Cancers</i> , 2021, 13, 2148. | 3.7 | 8 |
| 10 | Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies. <i>Cancer Treatment Reviews</i> , 2021, 97, 102202. | 7.7 | 14 |
| 11 | Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, 'Real-Life', Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2021, , . | 2.3 | 8 |
| 12 | Conversion therapy with encorafenib and cetuximab for chemo-refractory BRAF V600E- mutated liver-limited colorectal cancer metastasis: the first case report.. <i>Clinical Colorectal Cancer</i> , 2021, , . | 2.3 | 1 |
| 13 | Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. <i>Frontiers in Oncology</i> , 2021, 11, 712053. | 2.8 | 5 |
| 14 | A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. <i>Supportive Care in Cancer</i> , 2021, 30, 2455. | 2.2 | 1 |
| 15 | Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association. <i>ESMO Open</i> , 2020, 5, e001001. | 4.5 | 11 |
| 16 | Atezotribe: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 683. | 2.6 | 53 |
| 17 | Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6386. | 4.1 | 15 |
| 18 | Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter 'SLAVE' Study. <i>Cancers</i> , 2020, 12, 1259. | 3.7 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. <i>Clinical Colorectal Cancer</i> , 2020, 19, 219-225. | 2.3 | 45 |
| 20 | Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. <i>Clinical Colorectal Cancer</i> , 2020, 19, 191-199.e6. | 2.3 | 20 |
| 21 | A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the "BRAF BeCool"™ study. <i>European Journal of Cancer</i> , 2019, 118, 121-130. | 2.8 | 51 |
| 22 | Clinical, pathological, and prognostic features of rare BRAF mutations in metastatic colorectal cancer: a bi-institutional retrospective analysis (REBUS study). <i>Annals of Oncology</i> , 2019, 30, iv87. | 1.2 | 0 |
| 23 | Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies. <i>Annals of Oncology</i> , 2019, 30, iv116. | 1.2 | 0 |
| 24 | PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target. <i>Cancers</i> , 2019, 11, 1765. | 3.7 | 54 |
| 25 | CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 121, 593-599. | 6.4 | 24 |
| 26 | Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. <i>European Journal of Cancer</i> , 2019, 109, 175-182. | 2.8 | 25 |
| 27 | Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-11. | 3.0 | 1 |
| 28 | Clinical, pathological and prognostic features of rare BRAF mutations (MTs) in metastatic colorectal cancer (mCRC): A bi-institutional retrospective analysis (REBUS study).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3554-3554. | 1.6 | 0 |
| 29 | Chemotherapy rechallenge or reintroduction (CTr/r), regofenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients (pts): A propensity score analysis of treatment beyond second-line (PROSERpINA Study).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3556-3556. | 1.6 | 3 |
| 30 | Colorectal cancer lung metastasis: Could multidisciplinary management suggest the right strategy?. <i>Journal of Clinical Oncology</i> , 2019, 37, e15039-e15039. | 1.6 | 0 |
| 31 | Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3550-3550. | 1.6 | 1 |
| 32 | Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi-institutional analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3540-3540. | 1.6 | 0 |
| 33 | Exosomes as novel prognostic biomarker in potentially resectable colorectal cancer liver metastatic (CCLM) patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3558-3558. | 1.6 | 0 |
| 34 | Efficacy of anti-EGFR-based treatment (tx) in second-line and beyond according to tumor location (TL) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A mono-institutional retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15038-e15038. | 1.6 | 0 |
| 35 | Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e471-e488. | 2.3 | 12 |
| 36 | Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for <i>RAS</i> and <i>BRAF</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 529. | 7.1 | 87 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy. <i>European Journal of Clinical Nutrition</i> , 2018, 72, 772-779. | 2.9 | 28 |
| 38 | Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III Colon Cancer. <i>JAMA Oncology</i> , 2018, 4, 1297. | 7.1 | 0 |
| 39 | TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000403. | 4.5 | 20 |
| 40 | The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2018, 18, 98. | 2.6 | 17 |
| 41 | A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice. <i>Colorectal Cancer</i> , 2018, 7, CRC01. | 0.8 | 3 |
| 42 | Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2017, 116, 318-323. | 6.4 | 29 |
| 43 | Potential role of polymorphisms in the transporter genes ENT1 and MATE1 / OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2017, 86, 197-206. | 2.8 | 22 |
| 44 | Tandem repeat variation near the <i>HIC1</i> (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2017, 123, 4506-4514. | 4.1 | 8 |
| 45 | Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). <i>ESMO Open</i> , 2017, 2, e000147. | 4.5 | 36 |
| 46 | TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017, 17, 408. | 2.6 | 28 |
| 47 | Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer. <i>Anticancer Research</i> , 2017, 37, 315-320. | 1.1 | 21 |
| 48 | Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , 2017, 49, 834-845. | 3.0 | 12 |
| 49 | Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 988-994. | 3.7 | 94 |
| 50 | Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2016, 6, 25195. | 3.3 | 25 |
| 51 | Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 30-36. | 6.4 | 56 |
| 52 | Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. <i>Annals of Oncology</i> , 2015, 26, 724-730. | 1.2 | 136 |
| 53 | First-line chemotherapy for mCRC—a review and evidence-based algorithm. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 607-619. | 27.6 | 138 |
| 54 | Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. <i>Annals of Oncology</i> , 2015, 26, 1188-1194. | 1.2 | 153 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | TAS-102 for the treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2015, 15, 1283-1292. | 2.4 | 12 |
| 56 | Role of <i>NRAS</i> mutations as prognostic and predictive markers in metastatic colorectal cancer. International Journal of Cancer, 2015, 136, 83-90. | 5.1 | 126 |
| 57 | FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.. Journal of Clinical Oncology, 2015, 33, 657-657. | 1.6 | 17 |
| 58 | Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management. Oncotarget, 2015, 6, 33982-33992. | 1.8 | 46 |
| 59 | Prospective study of EGFR intron 1 (CA) _n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. Pharmacogenomics Journal, 2014, 14, 322-327. | 2.0 | 11 |
| 60 | EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Targeted Oncology, 2014, 9, 205-214. | 3.6 | 27 |
| 61 | Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. New England Journal of Medicine, 2014, 371, 1609-1618. | 27.0 | 845 |
| 62 | Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.. Journal of Clinical Oncology, 2014, 32, 3596-3596. | 1.6 | 4 |
| 63 | Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial.. Journal of Clinical Oncology, 2014, 32, TPS3664-TPS3664. | 1.6 | 2 |
| 64 | The Role of Metronomic Chemotherapy in the Treatment of Metastatic Colorectal Cancer Patients. , 2014, , 135-142. | | 0 |
| 65 | Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. British Journal of Cancer, 2013, 108, 2549-2556. | 6.4 | 51 |
| 66 | FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS,) Tj ETQqO O O rgBT /Overlock 10 Tf 50 Nord Ovest (GONO). Annals of Oncology, 2013, 24, 2062-2067. | 1.2 | 86 |
| 67 | FOLFOXIRI/Bevacizumab Versus FOLFIRI/Bevacizumab as First-Line Treatment in Unresectable Metastatic Colorectal Cancer: Results of Phase III Tribe Trial by Gono Group. Annals of Oncology, 2013, 24, iv21. | 1.2 | 5 |
| 68 | Long-Survivors with Lung Metastases and Kras Mutations Have an Increased Risk to Develop Brain Metastases From Colorectal Cancer. Annals of Oncology, 2013, 24, iv15. | 1.2 | 1 |
| 69 | Prospective Analysis of the Early Modulation of Plasma Amphiregulin During Treatment with Cetuximab and Irinotecan in Metastatic Colorectal Cancer Patients. Annals of Oncology, 2013, 24, iv28. | 1.2 | 0 |
| 70 | Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. PLoS ONE, 2013, 8, e66774. | 2.5 | 64 |
| 71 | Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Annals of Oncology, 2012, 23, 2072-2077. | 1.2 | 108 |
| 72 | Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. Annals of Oncology, 2012, 23, 135-141. | 1.2 | 79 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen. <i>Clinical Colorectal Cancer</i> , 2012, 11, 71-76. | 2.3 | 17 |
| 74 | EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. <i>Annals of Oncology</i> , 2012, 23, 1370-1371. | 1.2 | 7 |
| 75 | An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2012, 23, 1207-1213. | 1.2 | 40 |
| 76 | Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 153-160. | 0.5 | 0 |
| 77 | P-0262 Prospective Evaluation of Candidate Snps of Vegf/Vegfr Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line Folfiri Plus Bevacizumab (BV). <i>Annals of Oncology</i> , 2012, 23, iv105-iv106. | 1.2 | 0 |
| 78 | P-0263 Prospective Study of Egfr Intron 1 CA Tandem Repeats as Predictive Factor of Benefit from Cetuximab and Irinotecan. <i>Annals of Oncology</i> , 2012, 23, iv106. | 1.2 | 0 |
| 79 | Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer. <i>Cancer</i> , 2012, 118, 1523-1532. | 4.1 | 34 |
| 80 | Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. <i>BMC Cancer</i> , 2011, 11, 247. | 2.6 | 69 |
| 81 | Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2011, 104, 1262-1269. | 6.4 | 85 |
| 82 | Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 243-251. | 4.4 | 31 |
| 83 | Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis. <i>Journal of the National Cancer Institute</i> , 2011, 103, 21-30. | 6.3 | 160 |
| 84 | Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients. <i>Current Cancer Drug Targets</i> , 2010, 10, 37-45. | 1.6 | 12 |
| 85 | Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 559-566. | 2.3 | 5 |
| 86 | Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. <i>Pharmacogenomics</i> , 2010, 11, 1247-1256. | 1.3 | 6 |
| 87 | High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. <i>Annals of Oncology</i> , 2010, 21, 1565. | 1.2 | 38 |
| 88 | Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. <i>Lancet Oncology</i> , The, 2010, 11, 845-852. | 10.7 | 234 |
| 89 | Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab+irinotecan. <i>Pharmacogenomics Journal</i> , 2010, 10, 458-464. | 2.0 | 109 |
| 90 | Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 58. | 8.6 | 46 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 91 | Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009, 1, 167-181. | 3.2 | 7 |
| 92 | Refractory neuroendocrine tumor response to liposomal doxorubicin and capecitabine. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 670-674. | 27.6 | 5 |
| 93 | KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2009, 101, 715-721. | 6.4 | 509 |
| 94 | High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice. <i>Oncologist</i> , 2008, 13, 1270-1275. | 3.7 | 218 |